Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. (Q37879814)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Raashid Ahmed Luqmani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Mary-Jane C J Guerry

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Paul Brogan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

David P D'Cruz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Lorraine Harper

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Charles D Pusey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Alan D Salama

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

David G I Scott

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Caroline O S Savage

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Richard A Watts

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

David R W Jayne

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

25 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

634-643

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21613248%20AND%20SRC:MED&resulttype=core&format=json

EULAR recommendations for the management of primary small and medium vessel vasculitis.

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Biologic therapy in primary systemic vasculitis of the young.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab for treatment of patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab for severe refractory pediatric Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Successful treatment of severe juvenile microscopic polyangiitis with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab in Churg-Strauss syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

High frequency of false-positive signals in a real-time PCR-based "Plus/Minus" assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER150